Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/20852Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Tsatsoulis, A. | en |
| dc.contributor.author | Vlachoyiannopoulos, P. G. | en |
| dc.contributor.author | Dalekos, G. N. | en |
| dc.contributor.author | Johnson, E. O. | en |
| dc.contributor.author | Moutsopoulos, H. M. | en |
| dc.date.accessioned | 2015-11-24T19:10:39Z | - |
| dc.date.available | 2015-11-24T19:10:39Z | - |
| dc.identifier.issn | 0014-2972 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/20852 | - |
| dc.rights | Default Licence | - |
| dc.subject | Adult | en |
| dc.subject | Aged | en |
| dc.subject | Antithyroid Agents/*therapeutic use | en |
| dc.subject | Female | en |
| dc.subject | Goiter/blood | en |
| dc.subject | Graves Disease/blood | en |
| dc.subject | Humans | en |
| dc.subject | Hyperthyroidism/*blood/drug therapy | en |
| dc.subject | Interleukin-1/*blood/physiology | en |
| dc.subject | Male | en |
| dc.subject | Middle Aged | en |
| dc.subject | Receptors, Interleukin-2/analysis | en |
| dc.title | Increased serum interleukin-1 beta during treatment of hyperthyroidism with antithyroid drugs | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/7498238 | - |
| heal.identifier.secondary | http://onlinelibrary.wiley.com/store/10.1111/j.1365-2362.1995.tb01981.x/asset/j.1365-2362.1995.tb01981.x.pdf?v=1&t=h0upjn83&s=5096f3c4107377a8d84db975caf66028b7e53abd | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 1995 | - |
| heal.abstract | Serum interleukin-1 beta (IL-1 beta) and soluble interleukin-2 receptor (sIL-2R) levels were examined in patients with hyperthyroidism due to Graves' disease (GD) and toxic nodular goitre (TNG) before and during antithyroid drug therapy. A total of 32 patients were studied; 23 patients (14 with GD and nine with TNG) were in a hyperthyroid state (group A) and nine patients (four with GD and five with TNG) were in a euthyroid state, under carbimazole or methimazole treatment (group B). Ten hyperthyroid patients from group A (seven with GD and three with TNG) were also examined while euthyroid on treatment (Subgroup A). Serum was taken from all patients for the measurement of sIL-2R, IL-1 beta, total T4 (TT4), total T3 (TT3) and TSH concentrations. The results were compared with those from 30 normal controls. Serum sIL-2R levels were higher in Group A (671.3 +/- 74.0 U mL-1, mean +/- SE), than in Group B (214.1 +/- 61.8 U mL-1) and controls (149 +/- 14.8 U mL-1), P < 0.001. Similarly, the subgroup of 10 patients had higher levels of sIL-2R during the hyperthyroid phase than while euthyroid (P < 0.001). There was a positive correlation between sIL-2R values and levels of T4 and T3. In contrast, serum IL-1 beta levels were higher in Group B patients (197.5 +/- 39.2 pg mL-1) compared with those in Group A (66.5 +/- 17 pg mL-1, P < 0.01).(ABSTRACT TRUNCATED AT 250 WORDS) | en |
| heal.journalName | Eur J Clin Invest | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Tsatsoulis-1995-Increased serum inte.pdf | 451.01 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
